Funded by the National Multiple Sclerosis Society, the study aims to identify care gaps and develop resources for women with ...
By driving a robust culture of innovation, the hub will provide a collaborative space to test and scale solutions with ...
PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative ...
This narrative review argues that vitamin D is clearly important for skeletal health during the first 1,000 days of life and ...
The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...
On March 30, 2026, the FDA approved a high dose regimen for Spinraza (nusinersen) for the treatment of spinal muscular atrophy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results